JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG



How to manage complications after sclerotherapy?

Dra. Lourdes Reina Vascular Department. Hospital Cruz Roja Madrid

Disclosure

Dra. Lourdes Reina

I have the following potential conflicts of interest to report:

Consulting

Employment in industry

Shareholder in a healthcare company

Owner of a healthcare company

Other(s)

I do not have any potential conflict of interest



How to manage complications after sclerotherapy

- Complications can happen even to the most expert hands
- Mandatory to know what they are and how to manage them
- Early treatment can minimize sequels
- Most of them are minor
- But we must be alert and trained to react properly and immediately to serious adverse events



How to manage complications after sclerotherapy

- Serious complications: rare
 - Anaphylaxis
 - Cerebrovascular accidents
 - Venous thromboembolism
 - •Tissue necrosis
 - Neurologic damage
- Minor complications: more frequent
 - •Matting
 - Pigmentation

Guex 2005, Gillet 2009, Cavezzi 2012, Gillet 2014, Rabe 2014

Systemic allergic reactions and anaphylaxis

- Extremely rare
- Emergency
- Unpredictable



• Always be prepared repeated exposures increases risk

immediate response

Emergency and systemic adverse reaction protocol

Reina L. Phlebolymphology 2017, Gillet 2014, Rabe 2014, Mowatt-Larssen E, 2014, Sampson HA 2006, Lieberman PL 2014, Simons FE 2011, Goldman MP 2017, Bunke-Paquette N 2014, Brzoza Zn 2007, Parsi K.2014, Scurr JRH 2007, Cavezzi A 2012

TREATMENT OF SYSTEMIC ADVERSE REACTION AFTER SCLEROTHERAPY HOSPITAL CRUZ ROJA MADRID

UNDERLYING

Early detection of symptoms Injection stopped immediately



JANUARY 25-27 2018

Large tissue necrosis: Intra-arterial injection

- Extremely rare: <70 cases
- High risk injections:
 - popliteal
 - inguinal
 - medial ankle
 - medial thigh
- Amputation 52,5%

No consensus or evidence-based guidelines on optimal management

immediate response to prevent amputation

Intra-arterial injection treatment protocol

Hafner F 2013, Fegan WG 1974, Parsi K 2016, Nitecki SS 2007, Biegeleisen K 1993

Hospital Central de la Cruz Roja

Intraarterial injection treatment

- If severe pain with injection, stop the injection immediately, leave the needle unchanged, aspirate blood and remaining sclerosing solution if possible.
- Immediate IV heparin (5000-10.000 UI HNF) and continue heparin therapy at a therapeutic dosage for 6 days or longer.
- Consider immediate catheter-directed arterial thrombolisis trombolysiis.
- 500 mg Acetylsalicylic acid IV continue acetylsalicylic acid 100 mg or 325 mg daily 6 days or longer.
- Dextran 10%, 500 mL/day IV 3 days.
- systemic steroids IV for at least 48 hours Continue oral Prednisona 0.75–1 mg/kg/day (max 50 mg day) with gradual reduction over 12 weeks.
- Analgesia with NAIDs, anxioliytic therapy and consider electrostimulation therapy
- Hyperbaric oxygen

Tissue and cutaneous necrosis

- Most frequent: ulceration
- All sclerosants
- Not always a physician mistake
- Rare and limited sequelae
- Several weeks after sclerotherapy
- Pain, inflammation, edema
- 4-6 weeks to heal
- small: 4 mm



Cutaneous necrosis: extravasation

Extravasation:

immediate response

- Vigorous massage in extravasation area
- Dilute the extravasated sclerosant as soon as possible:
 - Hypertonic sclerosants: huge saline solution (10/1)
 - STS 3%: Hyaluronidase



Cutaneous necrosis: Venoarterial reflex vasospasm

Treatment:

- vasodilators (2% nitroglycerine ointment) immediate response
- Antiplatelets oral
- **NSAIDS** oral
- Systemic **anticoagulant** and **steroids** if extensive necrosis anticipated





Reina L 2017, Cavezzi 2012, Schuller-Petrovic S 2011, Miyake RK 2012, Tran D 2007

ONTROVERSIES & UPDATE

Cutaneous necrosis

Excision of the ulcer

speeds healing and decreases pain with aceptable scar



Transient neurologic events: visual disturbances and migraines

Nonspecific treatment:

- Neurologic evaluation and, DVT,
 PE and RLS screening
- Trendelenburg position and 100% oxygen
- Headaches: analgesia and triptans in selected cases



immediate response

Reina L 2017, International headache Society ICHD guidelines 2017

Ischemic neurological events: TIA and stroke

- TIA:
 - 5 published, all RLS, all after foam, and immediate onset
- STROKE:
 - 0,01%
 - 13 published cases:
 - RLS (FOP) etiologic factor most frequent

 - 4 after liquid, 9 after foam
 3 partial recovery, 9 total recovery
 Immediate (paradoxical gas embolism)
 - With a delayed onset (paradoxical clot embolism)
 - 3/13 patients no gas, no clot discovered

Hospital Central Cruz Roja

TIA o STROKE after foam with early onset

immediate response 100% Oxygen immediately • Place the patient in a head-down position for up to 10 minutes to clear bubbles from the cerebral circulation Paradoxical • Confirm gas bubbles in arterial circulation by images tests gas as soon as possible embolism Transfer the patient to a hyperbaric chamber treatment Anticoagulation heparin IV with PTT >2 Consider thrombolysis therapy with tissue plasminogen activator in selected cases • If FOP, closure in a second step

Bush RG 2008, , Parsi K 2011, Leslie-Mazwi TM 2009, Jauch EC 2013, Hanisch F 2004, Asbjomsen CB 2012, Reina L 2017



TIA or STROKE after foam with early onset

 Paradoxical gas embolism confirmed by imaging of bubbles in the intracranial arterial circulation as soon as possible



TIA or STROKE after foam with early onset

Hyperbaric oxygen therapy:

- Controversial results
- No routine use



Bush RG 2008, Asbjomsen CB 2012, Parsi K 2011, Reina L 2017

TIA or STROKE with delayed onset

Paradoxical clot embolism treatment

- STROKE guidelines recommendations
- Thrombolysis in selected cases

Venous Thromboembolism

- <3%
- Most asymptomatic and located in lower leg



Gillet 2009, Gillet JL 2014, Holbrook A 2012, Guex 2009, Coleridge 2006

Venous Thromboembolism

Treatment: No evidence based recommendations Depends on risk factors and extension of DVT

- Distal non occlusive DVT without risk factors has benign evolution with rapid recanalization: ambulation and compression, or NSAIDS or short LMWH or follow-up with ecodoppler
 - Proximal DVT:
 oral anticoagulation 3-6 months look for risk factors for DVT

Gillet 2009, Gillet JL 2014, Holbrook A 2012, Guex 2009, Coleridge 2006

Superficial venous thrombosis

- Part of the process more than a complication
- Complication if there is an extension beyond the treated area or an excessive inflammation
- Incidence depends on individual understandings so highly variable (0-45,8%)







Superficial venous thrombosis

DVT screening

Treatment:

- •Minor (most frequent): no treatment or coagula extraction
- •Symptomatic:
 - coagula extraction
 - ·ambulation
 - compression
 - **·NSAIDS**
 - ·LMWH if extensive or affects SFJ

Galanaud JP 2011, Goldman MP 2017, Holbrook A 2012



Nerve injury

- Very rare (0,02%)
- Sural and saphenous nerve
- Popliteal fossa and leg
- Transient paresthesia and dysesthesia (can last 6 months)



Dr. Pérez Monreal photo

Treatment:

- **NSAIDS** in minor cases
- Neurotropic agents in long-term
- Local infiltration with steroids and anesthetics

Matting

- Treatment technics:
 - no treated underlying reflux
 - high concentration, volume or pressure injection:
 - inflammatory reaction or excessive vein obstruction with angiogenesis
- Risk factors:
 - obesity, female, women, estrogens treatment, long duration of spider, family history of telangiectasia



Palm MD 2010, Kern P 2004, Goldman MP 1995

Matting

Look for and eliminate underlying reflux and residual veins with noninflammatory sclerotherapy or phlebectomy



• If no underlying reflux: Wait

- better than multiple treatments with stronger liquid sclerosants
- mild anti-inflammatory cream and follow up with photos until resolution

Goldman MP 2017, Palm MD 2010, Goldman MP 1995

CONTROVERSIES & UPDAT

Residual pigmentation

- 3-4 weeks of sclerotherapy
- 10-30% short term
- 70% resolution at 6 months
- 10% >1-2 year
- Combination of hemosiderin (extravasated red cells) and melanin pigment (inflammatory process)



Gillet JL 2009, Goldman MP 2017, Palm MD 2010



 Look for underlying reflux and eliminate it



Munavalli GS 2007, Palm MD 2010, Rabe E 2014

• Extracting intravascular coagulum expedites resolution





Kern P 2007, Scultetus AH 2003

Compression:

 anti-inflammatory effects, decrease chronic venous hypertension and helps coagula resolution





Rabe E 2014

CONTROVERSIES & UPDAT

Residual pigmentation

•Time is the first line of treatment

•Most patients spontaneous resolution within the first year



Munavalli GS 2007, Palm MD 2010, Rabe E 2014

Bleaching agents that affect melanocytic usually ineffective

Exfoliation with mild peeling agents Chelation of the subcutaneous iron deposition Q-switched laser therapy and intense pulse light

can help



Izzo M 2995, Lopez L 2001, Bissett DL 1994, Thibault P 1992. Goldman MP 1992, Tafazzoli A 2000, Weiss RA 2004, Beasley KL 2004, Freedman JR 2014, Reina L 2017

Transitory general effects

• Chest tightness, dry cough, nausea and a metallic taste



- Treatment similar to transitory neurologic disturbances:
 - Trendelenburg position

immediate response

- 100% O2 therapy
- Evaluate neurologic and cardiovascular state

Frullini A 2011, Parsi K 2011

Conclusions

Serious adverse events are very rare:

- there are no evidence-based recommendations to manage them
- most treatment options are based on anecdotal experience or data extrapolated from others pathologies

Conclusions

- EMERGENCY PLAN :
 - Neurologic deficit
 - Intra-arterial injection
 - Systemic adverse reaction or anaphylaxis
- TRANSPORT TO EMERGENCY SERVICES
- ACCESS TO HYPERBARIC THERAPY
- OXYGEN THERAPY

Reina L. Phlebolymphology 2017



How to manage complications after sclerotherapy

- Minor complications require:
 - Time
 - Follow-up by the practitioner
 - Adherence with post-sclerotherapy treatment by the patient

Phlebolymphology

Vol 24 • No. 3 • 2017 • P117-172

No. 93

Small saphenous vein interventional treatment	119
Jean-Luc GERARD (France)	
How to manage complications after sclerotherapy	130
Lourdes REINA, (Spain)	
Diagnosis and treatment of situational great	144
saphenous vein reflux in daily medical practice	
Yu, T. TSUKANOV, A. Yu, TSUKANOV (Russia)	
New diagnostic modalities in lymphedema	152
Sarah THOMIS (Belgium)	
Prevention and treatment of venous disorders during	160
pregnancy and the postpartum period	
Djordje RADAK, Slobodan TANASKOVIC (Serbia)	

